Athira Pharma, Inc.
(NASDAQ GS: ATHA)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Athira Pharma, Inc. ("Athira" or the "Company") on behalf of stockholders. A class action complaint has been filed against Athira. The complaint alleges defendants made materially false and misleading statements and omissions, including that: (i) defendants' statements in the Company's IPO materials concerning Company President and CEO Leen Kawas' ("Kawas") qualifications were materially false or misleading when made because they failed to disclose that Kawas' research publications regarding the compound underlying the Company's lead product contained altered images and that the dissertation Kawas published in connection with obtaining her Ph.D. was obtained with falsified research; (ii) defendants' statements in the IPO materials regarding their intellectual property and licensing agreements were materially false or misleading when made because they failed to disclose that at least four studies with images that were doctored by Kawas laid the biological groundwork for Athira's patents and the Company's approach to treating Alzheimer's disease and other conditions; and (iii) the submission of fraudulent data to the U.S. Patent and Trademark Office renders the entirety of such a patent, and any related patents, unenforceable and consequently worthless. Thus, the failure to disclose that the patents were based on doctored images, and the attendant risk of invalidation of the patents, was false and misleading.